Alaunos Reports Positive Preclinical Data for Obesity Candidate

An announcement from Alaunos Therapeutics ( (TCRT) ) is now available.

On March 2, 2026, Alaunos Therapeutics, Inc. reported positive preclinical proof-of-concept data from two non-GLP diet-induced obesity mouse studies of its lead small-molecule candidate ALN1003, a non-hormonal oral therapy for obesity and related metabolic disorders. The studies showed dose-related body weight loss, reductions in liver weight, favorable shifts in fat and lean mass, and improvements in glucose, cholesterol, and select liver injury biomarkers compared with untreated controls.

ALN1003 was generally well tolerated, with only mild, reversible hypolocomotion in one study and slight dehydration in two high-dose animals in the other, and visual organ assessments suggested reduced liver fat and healthier adipose tissue profiles in treated mice. These early findings provide encouraging signals on efficacy and potential safety that will guide Alaunos’s ongoing preclinical, formulation, and manufacturing initiatives, supporting its bid to position ALN1003 as a differentiated entrant in the rapidly evolving obesity therapeutics market.

Spark’s Take on TCRT Stock

According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.

Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.

To see Spark’s full report on TCRT stock, click here.

More about Alaunos Therapeutics

Alaunos Therapeutics, Inc. is an early-stage biotechnology company focused on developing small-molecule therapies for obesity and related metabolic disorders, including metabolic dysfunction-associated steatotic liver disease. Its lead candidate, ALN1003, is being designed as a differentiated, non-hormonal, non-incretin oral treatment that aims to provide an alternative to current hormone-based obesity drugs.

On March 2, 2026, Alaunos reported positive preclinical proof-of-concept data from two non-GLP diet-induced obesity mouse studies of ALN1003, showing dose-dependent weight loss, favorable body composition changes, reduced liver weight, and improvements in select metabolic and liver injury biomarkers versus control animals. The drug was generally well tolerated in both models, with only mild, reversible side effects observed, and the results are expected to inform further preclinical work, formulation optimization, and manufacturing refinement as the company advances ALN1003 within the competitive obesity treatment landscape.

Average Trading Volume: 34,430

Technical Sentiment Signal: Sell

Current Market Cap: $7.12M

For a thorough assessment of TCRT stock, go to TipRanks’ Stock Analysis page.